News | April 24, 2026
Boston Scientific surges into 2026 with double-digit sales growth & record quarterly profit jump
Growth was broad-based across segments
Growth was broad-based across segments
Aims to boost speed & precision in patient care
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Stakeholders call for coordinated action on diagnostics, vaccines, and health system readiness as the monsoon season approaches
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Manoj has over two decades of experience in healthcare operations and biomedical engineering
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
Subscribe To Our Newsletter & Stay Updated
